- Home
- ANGH vs FGEN Comparison
ANGH vs FGEN Comparison
Compare ANGH & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- FGEN
- Stock Information
- Founded
- ANGH 2012
- FGEN 1993
- Country
- ANGH United Arab Emirates
- FGEN United States
- Employees
- ANGH N/A
- FGEN N/A
- Industry
- ANGH Telecommunications Equipment
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- FGEN Health Care
- Exchange
- ANGH Nasdaq
- FGEN Nasdaq
- Market Cap
- ANGH 32.1M
- FGEN 33.5M
- IPO Year
- ANGH N/A
- FGEN 2014
- Fundamental
- Price
- ANGH $0.48
- FGEN $6.30
- Analyst Decision
- ANGH
- FGEN Strong Buy
- Analyst Count
- ANGH 0
- FGEN 1
- Target Price
- ANGH N/A
- FGEN $250.00
- AVG Volume (30 Days)
- ANGH 10.8K
- FGEN 61.5K
- Earning Date
- ANGH 07-15-2025
- FGEN 08-05-2025
- Dividend Yield
- ANGH N/A
- FGEN N/A
- EPS Growth
- ANGH N/A
- FGEN N/A
- EPS
- ANGH N/A
- FGEN N/A
- Revenue
- ANGH $78,093,405.00
- FGEN $6,996,000.00
- Revenue This Year
- ANGH N/A
- FGEN N/A
- Revenue Next Year
- ANGH N/A
- FGEN N/A
- P/E Ratio
- ANGH N/A
- FGEN N/A
- Revenue Growth
- ANGH 88.72
- FGEN N/A
- 52 Week Low
- ANGH $0.42
- FGEN $4.50
- 52 Week High
- ANGH $1.08
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- ANGH 42.15
- FGEN 51.09
- Support Level
- ANGH $0.47
- FGEN $5.37
- Resistance Level
- ANGH $0.52
- FGEN $5.73
- Average True Range (ATR)
- ANGH 0.02
- FGEN 0.40
- MACD
- ANGH 0.00
- FGEN 0.14
- Stochastic Oscillator
- ANGH 15.10
- FGEN 98.80
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.